Recently, the 2023 edition of the "China Drug Administration Yearbook" published by the State Administration for Market Regulation has been officially released. Tianjiquan Group has been listed in the "China Drug Administration Yearbook" (2023) for its excellent corporate image, high-quality medical products, and outstanding services. This not only demonstrates the outstanding achievements of Tianjiquan Group in developing innovative products and the market position of the brand, but also once again proves the recognition of Tianjiquan and its research and development products by the National Medical Products Administration.
China Drug Administration Yearbook (2023)
The board of directors of Tianjiquan Group attaches great importance to product innovation and research and development